Bull of the Day: Access Pharma

Access Pharma (ACCP) is a biopharmaceutical company focused on developing a range of pharmaceuticals primarily based upon the company s three key drug delivery technologies. Access currently has one approved product MuGard for the management of oral mucositis. Two cancer drug candidates ProLindac and Thiarabine are in phase II studies.

We are especially impressed with the company s Cobalaminbased oral drug delivery system. Both oral insulin and human growth hormone have achieved unprecedented oral bioavailability in animal models. Current share price is undervalued. We encourage investors accumulate the company s shares. Our six to twelve-month price target is $8.

ACCESS PHARMA (ACCP): Free Stock Analysis Report

About Zacks Investment Research 1767 Articles

Zacks Investment Research is one of the most highly regarded firms in the investment industry. In 1978 Zacks originated the concept of utilizing earnings estimates revisions to make profitable investment decisions. Zacks offers multiple investment products and services to help investors achieve superior returns.

Visit: Zacks.com

Be the first to comment

Leave a Reply

Your email address will not be published.


*